Skip to main content

Advertisement

SpringerLink
Log in

Ductal Carcinoma In Situ: Treatment Update and Current Trends

  • Breast Cancer (B Overmoyer, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Ductal carcinoma in situ (DCIS) traditionally has been managed through various combinations of surgery, radiation, and endocrine therapy. However, concern for under- or over-treatment of DCIS has led many surgeons to question historically standardized approaches and instead begin to tailor treatment based on individual prognostic indicators. Recent and ongoing clinical trials have investigated the potential for active surveillance in DCIS, the possibility of eliminating radiation therapy (RT), and ways in which adjuvant systemic therapy may be refined. This review will summarize the current trends in the treatment of DCIS, as well as highlight the most pertinent clinical trials that are shaping management today.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27:279–88.

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  3. Allegra CJ, Aberle DR, Ganschow P, Han SM, Lee CN, Millon-Underwood S, et al. National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma in Situ September 22–24, 2009. J Natl Cancer Inst. 2010;102:161–9.

    Article  PubMed  Google Scholar 

  4. Zujewski JA, Harlan LC, Morrell DM, Stevens JL. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat. 2011;127:251–7.

    Article  PubMed  Google Scholar 

  5. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430–41.

    Article  CAS  PubMed  Google Scholar 

  6. Kuerer HM. Ductal carcinoma in situ: treatment or active surveillance? Expert Rev Anticancer Ther. 2015;7:777–85.

    Article  Google Scholar 

  7. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186:337–43.

    Article  PubMed  Google Scholar 

  8. Sue GR, Lannin DR, Au AF, Narayan D, Chagpar AB. Factors associated with decision to pursue mastectomy and breast reconstruction in the treatment of ductal carcinoma of the breast. Am J Surg. 2013;206:682–5.

    Article  PubMed  Google Scholar 

  9. Elsayegh N, Kuerer HM, Lin H, Guiterrez Barrera AM, Jackson M, Muse KL, et al. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA gene testing. Ann Surg Oncol. 2014;11:3466–72.

    Article  Google Scholar 

  10. Rutter CE, Park HS, Killelea BK, Evans SB. Growing use of mastectomy for ductal carcinoma in situ of the breast among young women in the United States. Ann Surg Oncol. 2015;7:2378–86.

    Article  Google Scholar 

  11. Ashfag A, McGhan LJ, Pockaj BA, Gray RJ, Bagaria SP, McLaughlin SA, et al. Impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy. Ann Surg Oncol. 2014;21:2934–40.

    Article  Google Scholar 

  12. Habermann EB, Thomsen KM, Hieken TJ, Boughey JC. Impact of availability of immediate breast reconstruction on bilateral mastectomy rates for breast cancer across the United States: data from the nationwide inpatient sample. Ann Surg Oncol. 2014;10:3290–6.

    Article  Google Scholar 

  13. Julian TB, Land SR, Fourchotte V, Haile SR, Fisher ER, Mamounas EP, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol. 2007;8:2202–8.

    Article  Google Scholar 

  14. Francis AM, Haugen CE, Grimes LM, Crow JR, Yi M, Mittendorf EA, et al. Is sentinel lymph node dissection warranted for patients with a diagnosis of ductal carcinoma in situ? Ann Surg Oncol. 2015. Study demonstrates potential to reserve SLND only for patients at high risk for invasive disease.

  15. Baxter NN, Virnig BA, Durham SB. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–8.

    Article  PubMed  Google Scholar 

  16. Silverstein MJ, Lagios MD. Use of predictors of recurrence to plan therapy for DCIS of the breast. Oncology. 1997.

  17. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast duct carcinoma in situ. Lancet. 1995;345:1154–7.

    Article  CAS  PubMed  Google Scholar 

  18. Silverstein M, Lagios M, Craig P, Waisman JR, Lewinsky BS, Colburn WJ, et al. The Van Nuys Prognostic Index for ductal carcinoma in situ. Breast J. 1996;2:38–40.

    Article  Google Scholar 

  19. Silverstein MJ, Buchanan C. Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast. 2003;12:457–71.

    Article  PubMed  Google Scholar 

  20. Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist. 2007;11:1276–87.

    Article  Google Scholar 

  21. Macdonald HR, Silverstein MJ, Lee LA, Ye W, Sanghavi P, Holmes DR, et al. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ. Am J Surg. 2006;192:420–2.

    Article  PubMed  Google Scholar 

  22. Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, et al. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013;13:4103–12. Study demonstrates that PMRT is only indicated for those patients with multiple close or positive margins.

    Article  Google Scholar 

  23. Cablioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, et al. Role for intraoperative margin assessment in patients undergoing breast-conserving therapy. Ann Surg Oncol. 2007;14:1458–71.

    Article  Google Scholar 

  24. Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving therapy alone. Breast Cancer Res Treat. 2015;152:389–98. Population-based validation of Oncotype DX DCIS Score to predict breast cancer recurrence with significant potential for clinical impact in stratifying patients to low, intermediate, and high-risk categories based on biologic profile of individual tumors.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Wells CJ, O’Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman LJ, et al. Evolving paradigm for the management of DCIS. J Am Coll Radiol. 2013;10:918–23.

    Article  PubMed  Google Scholar 

  26. Francis A, Fallowfield L, Rea D. The LORIS Trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol). 2015;27:6–8. Future results have potential to significantly impact management of DCIS such that low-risk patients may undergo active surveillance rather than surgery and/or RT.

    Article  CAS  Google Scholar 

  27. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.

    CAS  PubMed  Google Scholar 

  28. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker N, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: results of the European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.

    Article  Google Scholar 

  29. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355:528–33.

    Article  CAS  PubMed  Google Scholar 

  30. Wehner P, Lagios MD, Silverstein MJ. DCIS treated with excision alone using the National Comprehensive Cancer Network guidelines. Ann Surg Oncol. 2013;10:3175–9.

    Article  Google Scholar 

  31. McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33:709–15. Though closed early due to low accrual, the study did demonstrate small benefit for RT in reducing local recurrence, even in low- and intermediate-risk patients with negative surgical margins.

    Article  CAS  PubMed  Google Scholar 

  32. http://www.eortc.org/research-groups/breast-cancer-group/ongoing-and-future-projects/. Accessed 9 July 2015.

  33. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105:701–10. Demonstrates that multi-gene assay provides powerful tool to individualize DCIS treatment and predict recurrence risk, though prospective data demonstrating outcome of patients based on selection for radiation versus observation currently is lacking.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Jeruss JS, Vicini FA, Beitsch PD. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann Surg Oncol. 2006;13:967–76.

    Article  PubMed  Google Scholar 

  35. Goyal S, Vicini F, Beitsch PD, Kuerer H, Keisch M, Motwani S, et al. Ductal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite registry trial with intergroup study E5194. Cancer. 2011;117:1149–55.

    Article  PubMed  Google Scholar 

  36. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. J Clin Pathol. 2002;55:14.

    Article  Google Scholar 

  37. Wapnir IL, Dignam JJ, Fisher B, Mamounas E, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232–61.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer. 2009;9:285.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, et al. Primary results of NRG Oncology/NSABP B-35: a clinical trial of anastrozole vs. tamoxifen in postmenopausal patients with DCIS. Presented at the American Society of Clinical Oncology 2015 Annual Meeting. Chicago, Illinois.

  41. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011;117:39–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013;142:415–21. Future results have potential to demonstrate that anti-HER2/neu therapy provides new, critical adjuvant option for DCIS.

    Article  CAS  PubMed  Google Scholar 

  43. Knopfelmacher A, Fox J, Lo Y, Shapiro N, Fineberg S. Correlation of histopathologic features of ductal carcinoma in situ of the breast with the Oncotype DX score. Modern Path. 2015;00:1–7. Study suggests that using PR-receptor positivity, mitotic count, and presence of inflammation could predict Oncotype DX Score.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Katrina B. Mitchell declares that she has no conflict of interest. Henry Kuerer has received research funding through a grant from Genomic Health, Inc., and has received compensation from Gerson Lehrman Group and Lightpoint Medical for service as a consultant/advisor and has received compensation from McGraw-Hill via patents, royalties, and other intellectual property.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Breast Surgical Oncology, MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX, 77030, USA

    Katrina B. Mitchell & Henry Kuerer

Authors
  1. Katrina B. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henry Kuerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry Kuerer.

Additional information

This article is part of the Topical Collection on Breast Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mitchell, K.B., Kuerer, H. Ductal Carcinoma In Situ: Treatment Update and Current Trends. Curr Oncol Rep 17, 48 (2015). https://doi.org/10.1007/s11912-015-0473-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-015-0473-x

Keywords

Search

Navigation